Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 4/20 | 0.66 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flerobuterol SCHEMBL20819557 | 1.00 | ADRB1 (0.66) | ADRB1ADRB2HIF1ACYP2D6NFKB1 | |
| Flerobuterol SCHEMBL30956705 | 1.00 | ADRB1 (0.66) | ADRB1ADRB2HIF1ACYP2D6NFKB1 | |
| Flerobuterol SCHEMBL29356232 | 1.00 | ADRB1 (0.66) | ADRB1ADRB2HIF1ACYP2D6NFKB1 | |
| Flerobuterol SCHEMBL10624514 | 0.98 | BLM (0.67) | ADRB1ADRB2HIF1ACYP2D6NFKB1 | |
| SCHEMBL30956709 | 0.87 | ADRB1 (0.58) | ADRB1ADRB2HIF1ACYP2D6NFKB1 | |
| SCHEMBL20819687 | 0.87 | ADRB1 (0.58) | ADRB1ADRB2HIF1ACYP2D6NFKB1 | |
| SCHEMBL30956714 | 0.87 | ADRB1 (0.58) | ADRB1ADRB2HIF1ACYP2D6NFKB1 | |
| SCHEMBL9820962 | 0.87 | ADRB1 (0.58) | ADRB1ADRB2HIF1ACYP2D6NFKB1 | |
| SCHEMBL20819586 | 0.85 | ADRB2 (0.56) | ADRB1ADRB2HIF1ACYP2D6NFKB1 | |
| SCHEMBL20819585 | 0.85 | ADRB2 (0.56) | ADRB1ADRB2HIF1ACYP2D6NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 429 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190125699-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | CIPHER PHARMACEUTICALS INC. (CA) | 2019-05-02 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20130237607-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | ASTION DEVELOPMENT A/S (DK) | 2013-09-12 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| EP-1719507-B1 | Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin | ASTION DEV AS (DK) | 2010-07-14 | — | — | EP | claimed |
| US-20090123391-A1 | Novel Formulations | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2009-05-14 | — | — | US | claimed |
| CN-101415428-A | Novel formulations | 3M INNOVATIVE PROPERTIES CO (GB) | 2009-04-22 | — | — | CN | claimed |
| EP-2012797-A2 | NOVEL FORMULATIONS | GLAXO GROUP LIMITED (GB) | 2009-01-14 | — | — | EP | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| WO-2003042162-A1 | PRODRUGS OF ANTIDEPRESSANTS AND THEIR USE FOR TREATING DEPRESSIONS | NEUROSEARCH A/S (DK) | 2003-05-22 | — | — | WO | claimed |
| US-5843347-A | Extrusion and freeze-drying method for preparing particles containing an active ingredient | LABORATOIRE L. LAFON (FR) | 1998-12-01 | — | — | US | claimed |
| EP-0690747-B1 | EXTRUSION AND FREEZE-DRYING METHOD FOR PREPARING PARTICLES CONTAINING AN ACTIVE INGREDIENT | LAFON LABOR (FR) | 1997-05-28 | — | — | EP | claimed |
| EP-0690747-A1 | EXTRUSION AND FREEZE-DRYING METHOD FOR PREPARING PARTICLES CONTAINING AN ACTIVE INGREDIENT | LAFON LABOR (FR) | 1996-01-10 | — | — | EP | claimed |
| WO-1994021371-A1 | EXTRUSION AND FREEZE-DRYING METHOD FOR PREPARING PARTICLES CONTAINING AN ACTIVE INGREDIENT | LABORATOIRE L. LAFON (FR) | 1994-09-29 | — | — | WO | claimed |
| US-4861801-A | Treatment of depression by using a fluorophenacylamine derivative | Lafon, Laboratoire L. (FR) | 1989-08-29 | — | — | US | claimed |
| US-4835315-A | Fluorophenacyl-amine derivatives and application thereof in therapeutics | LABORATOIRE L. LAFON (FR) | 1989-05-30 | — | — | US | claimed |
| EP-0146443-B1 | (-)-1-(2-FLUOROPHENYL)-2-TERTIOBUTYLAMINO-1-ETHANOL AND THERAPEUTICAL USE | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1988-04-27 | — | — | EP | claimed |
| EP-0060954-B1 | DERIVATIVES OF FLUOROPHENACYL AMINES AND THEIR THERAPEUTIC USE | LABORATOIRE L. LAFON Société anonyme dite: (FR) | 1984-08-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237607-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | ADRB2, ADRB1, ADRA2A | ADRB1 2/4885ADRB2 1/4885HIF1A 2127/4885 |
| US-20090123391-A1 | Novel Formulations | PFN1, CCL11, MFAP1 | ADRB1 79/4885ADRB2 61/4885HIF1A 1040/4885 |
| US-20190125699-A1 | TREATMENT OF CONNECTIVE TISSUE DISEASES OF THE SKIN | ADRB2, ADRB1, ADRA2A | ADRB1 2/4885ADRB2 1/4885HIF1A 2127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.